We Bring Innovation to Life

Supporting high volume drug delivery

Bring your innovation to life with Molly® 2.25, a high-volume variation of SHL’s classic Molly® auto injector, designed with improved features for enhanced production and usability

June 03-06 | BIO International Convention 2019 

Booth #2455

Molly® 2.25

Molly® is an incredibly intuitive and easy-to-use auto injector built with a preconfigured technology developed to minimize customer investments and speed up development timelines.

Bigger Volume

Close

Built for higher volume injections, Molly® 2.25 supports the trends for injection volumes in the 1-2.25mL range. This allows new drugs to be delivered in auto injectors and launched products to be dosed less frequently.

Better Grip

Close

Deepened ridges on Molly®’s cap enhances grip. Its flare-shaped top facilitates cap removal, and its rectangular contour prevents unwanted rolling to ance the device’s safety.

Easier Handling

Close

As a preconfigured offering, Molly® 2.25 is designed to be easily understood and accepted by a variety of patient groups. Having inherited the classic Molly®’s 2-step process, Molly® 2.25 is as compact, intuitive and easy to use.

Faster Timelines

Close

SHL’s final assembly, labeling and packaging services were established to create added value for our partners following the successful design and development of their device, resulting in a fully integrated service from device design to commercialization.

Preconfigured Technology

Close

A high-volume variation of SHL's classic Molly® auto injector, Molly® 2.25 is a preconfigured device that can also support various levels of customization to meet client specifications. 

Preconfigured Technology

A high-volume variation of SHL's classic Molly® auto injector, Molly® 2.25 is a preconfigured device that can also

support various levels of customization

to meet client specifications. 

Easier Handling

As a preconfigured offering, Molly® 2.25 is designed to be easily understood and accepted by a variety of patient groups. Having inherited the classic Molly®’s 2-step process, Molly® 2.25 is as compact, intuitive and easy to use.

Better Grip

Deepened ridges on Molly®’s cap enhances grip. Its flare-shaped top facilitates cap removal, and its rectangular contour prevents unwanted rolling to enhance the device’s safety.

Bigger Volume

Built for higher volume injections, Molly® 2.25 supports the trends for injection volumes in the 1-2.25mL range. This allows new drugs to be delivered in auto injectors and launched products to be dosed less frequently.

Faster Timelines

SHL’s final assembly, labeling and packaging services were established to create added value for our partners following the successful design and development of their device, resulting in a fully integrated service from device design to commercialization.

Go to article: Home | The absence of antivenomGo to article: In this issueGo to article: Daiichi JitsugyoGo to article: ContentsGo to article: Capsugel Company InsightGo to article: CapsugelGo to article: NewsGo to article: Scandinavian Health Ltd.Go to article: International Cannabis and Cannabinoid Institute (ICCI) Company InsightGo to article: International Cannabis and Cannabinoid Institute (ICCI)Go to article: The pharma industry briefingGo to article: TSS Company InsightGo to article: TSS ABGo to article: Action Medical Research: celebrating decades of discovery Go to article: Swiss WorldCargoGo to article: Gerteis Company InsightGo to article: GerteisGo to article: Moehs Iberica SLGo to article: Owen MumfordGo to article: How government policy has shaped China’s pharma phenomenonGo to article: HOF Sonderanlagenbau Company InsightGo to article: HOF SonderanlagenbauGo to article: Novo NordiskGo to article: Snake venom in pharma; access to antivenom is a topic that needs attentionGo to article: Phoenix Group Company InsightGo to article: Phoenix Group Go to article: ME Logistic ServicesGo to article: Discussing drug policy reform with psychedelics campaigner Amanda FeildingGo to article: Finnair Cargo | Company InsightGo to article: Finnair CargoGo to article: Aseptic TechnologiesGo to article: False flags: are search engines benefiting rogue online pharmacies?Go to article: CBDepot Company InsightGo to article: CBDepotGo to article: Wilco Company Insight Go to article: WilcoGo to article: The Mighty: how patients and pharma align in the age of social media Go to article: Pharma Support Services Company InsightGo to article: Pharma Support ServicesGo to article: MicronovaGo to article: Inside Italy’s pharmaceutical industry Go to article: KlingeGo to article: BEAGo to article: Erdmann Design SwitzerlandGo to article: Inside the UK’s first vaccines innovation centreGo to article: AralabGo to article: Applikon BiotechnologyGo to article: BaxterGo to article: NymiGo to article: Fostering closer collaboration between manufacturing & regulatory functionsGo to article: EmisphereGo to article: SephaGo to article: Contract Pharmaceuticals Limited CanadaGo to article: EventsGo to article: Pfanstiehl Company InsightGo to article: PfanstiehlGo to article: Next issueGo to article: PolpharmaGo to article: BioAdvice